Lumateperone Shows Greatest Efficacy Improvement Among Adjunctive MDD Treatments in New Network Meta-Analysis

A new network meta-analysis comparing lumateperone (Caplyta; Johnson & Johnson) to other FDA-approved atypical antipsychotics as adjunctive treatment for major depressive disorder (MDD) found that lumateperone demonstrated the largest effect sizes across all four efficacy outcomes evaluated, while also showing a favorable weight and tolerability profile relative to comparators.

"This analysis is valuable because it gives us indirect comparative insights in a space where we don't have head-to-head trials, which may inform treatment discussions in everyday clinical practice," Andrew J. Cutler, MD, lead author and chief medical officer of the Neuroscience Education Institute and clinical professor of psychiatry at SUNY Upstate Medical University, said in a press release.

The analysis drew on data from 10 registrational randomized clinical trials and was presented as a late-breaking session at the 2026 Neuroscience Education Institute Spring Congress in Kissimmee, Florida.

Using a star-shaped network anchored on placebo plus antidepressant therapy (ADT), researchers assessed five treatment nodes across four efficacy and four safety outcomes. On the Montgomery-Åsberg Depression Rating Scale (MADRS), lumateperone produced a mean change from baseline of -4.71 points (95% credible interval [CrI] -5.78, -3.63) and demonstrated odds ratios of 2.33 (95% CrI 1.77, 3.05) for MADRS response and 2.22 (95% CrI 1.57, 3.07) for MADRS remission. Change from baseline on the Clinical Global Impressions-Severity scale favored lumateperone with a mean difference of -0.60 (95% CrI -0.74, -0.46). In direct pairwise comparisons anchored to lumateperone, it was favored over all comparators on both MADRS and CGI-S change from baseline.

On weight-related outcomes, lumateperone showed no statistically significant weight gain compared with placebo plus ADT, ranking most favorably among all 5 nodes on mean weight change (MD -0.08; 95% CrI -0.30, 0.13) and on the proportion of patients experiencing a clinically meaningful weight increase of 7% or more (OR 0.41; 95% CrI 0.04, 1.42). The agent carried a 100% probability of superiority versus all comparators on mean weight change.

Lumateperone was the only treatment in the analysis with akathisia risk comparable to placebo plus ADT. Somnolence risk was elevated relative to placebo across all agents evaluated, including lumateperone, though pairwise comparisons showed comparable somnolence risk between lumateperone and two of its four comparators.

"This analysis is valuable because it gives us indirect comparative insights in a space where we don't have head-to-head trials, which may inform treatment discussions in everyday clinical practice," said Andrew J. Cutler, MD, lead author and chief medical officer of the Neuroscience Education Institute and clinical professor of psychiatry at SUNY Upstate Medical University.

The investigators note that NMA findings rely on indirect comparisons across trials that may differ in design and patient populations, and results should be interpreted alongside the full body of clinical evidence.

References:

1. Cutler AJ, Lemyre A, Zhang Q, et al. Efficacy and Safety of Lumateperone versus Atypical Antipsychotics as Adjunctive Therapy in Major Depressive Disorder: A Pooled-Dose Network Meta-Analysis. 2026 Neuroscience Education Institute (NEI) Spring Congress; May 1-3, 2026; Kissimmee, FL.
2. Johnson & Johnson. CAPLYTA® (lumateperone) showed greatest improvement across key efficacy outcomes among adjunctive MDD treatments in new network meta-analysis. News release. May 4, 2026. Accessed May 4, 2026.